Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Efinopegdutide Phase 2b MASH Results

A 52-week phase 2b trial found stronger MASH resolution with efinopegdutide than placebo, while fibrosis and safety results varied by dose.

Why we wrote this. The trial produced strong MASH-resolution numbers, but its dose pattern, comparator design and surrogate endpoints need careful reading before anyone calls it a winner.

In this article (6 sections)
  1. What the phase 2b trial tested
  2. MASH resolution was higher than placebo
  3. The fibrosis result varied by dose
  4. Safety and tolerability matter here
  5. How semaglutide changes the context
  6. What we don't yet know

A phase 2b trial found that efinopegdutide produced higher rates of metabolic dysfunction-associated steatohepatitis (MASH) resolution than placebo after 52 weeks. The clearest fibrosis result appeared with the 7 mg study dose, but the pattern was not a simple more-is-better dose response. Gastrointestinal adverse events and treatment discontinuations were most common in the 10 mg group[1]. Efinopegdutide remains an investigational medicine, so these results do not establish an approved treatment or a dose for clinical use.

The trial also included an open-label semaglutide arm. That gives useful context, but it does not turn the study into a definitive head-to-head test of efinopegdutide against semaglutide. The paper's reported efficacy comparisons were against placebo, and the semaglutide group was not blinded in the same way as the placebo-controlled groups[1].

What the phase 2b trial tested

Efinopegdutide is a once-weekly co-agonist that acts at GLP-1 and glucagon receptors. Investigators enrolled adults with biopsy-confirmed, noncirrhotic MASH and stage F2 or F3 fibrosis. The study was conducted at 176 academic and community centres in 26 countries. It randomly assigned 386 people across five groups: efinopegdutide 4 mg, 7 mg or 10 mg, placebo, or open-label semaglutide 2.4 mg. Of those assigned, 381 received at least one dose and entered the analysis[1].

The registered protocol describes a randomised parallel study with participants, investigators and outcome assessors masked for the blinded arms. Treatment lasted 52 weeks. The primary efficacy endpoint was MASH resolution without worsening of fibrosis, judged from liver biopsies. A key secondary endpoint asked whether fibrosis improved by at least one stage without worsening steatohepatitis[2]. These are histology endpoints, not proof that the treatment prevents cirrhosis, liver failure or death.

MASH resolution was higher than placebo

At week 52, MASH resolution without fibrosis worsening occurred in 31 of 55 evaluable participants (56%) in the 4 mg group, 31 of 49 (63%) in the 7 mg group and 35 of 57 (61%) in the 10 mg group. The placebo result was 7 of 53 participants (13%). Each efinopegdutide dose had a statistically significant difference from placebo for this endpoint, with all three reported p values below 0.0001[1].

The semaglutide arm recorded MASH resolution without fibrosis worsening in 26 of 49 evaluable participants (53%)[1]. It is tempting to rank 53%, 56%, 61% and 63% as though they came from a direct contest. That would overread the study. The abstract reports placebo comparisons for efinopegdutide, not a powered superiority analysis against semaglutide. Different numbers of participants also contributed evaluable biopsies to each endpoint.

The fibrosis result varied by dose

Fibrosis improvement of at least one stage without worsening steatohepatitis occurred in 32 of 75 participants (43%) with 4 mg, 39 of 75 (52%) with 7 mg and 26 of 77 (34%) with 10 mg. Placebo reached the endpoint in 16 of 77 participants (21%). The 4 mg and 7 mg comparisons with placebo were statistically significant. The 10 mg comparison was not, with a reported p value of 0.072 and a 95% confidence interval for the difference that crossed zero[1].

In the semaglutide group, 16 of 65 participants (25%) met this fibrosis endpoint[1]. Again, that figure is context rather than evidence that one medicine is superior to the other. A properly designed head-to-head trial would need a prespecified comparison, adequate statistical power and consistent masking. This phase 2b study primarily establishes whether efinopegdutide showed enough activity and acceptable safety to justify further development.

Safety and tolerability matter here

Gastrointestinal problems were the most frequently reported adverse events with efinopegdutide, and rates were highest in the 10 mg group. Adverse events led to treatment discontinuation in 9 of 79 participants (11%) assigned 10 mg. The corresponding range across the lower efinopegdutide doses was 3% to 4%, while one placebo participant (1%) discontinued because of an adverse event[1]. The trial abstract does not provide a complete event-by-event safety table, so it cannot answer questions about uncommon or long-term harms.

The dose pattern is one reason the 7 mg result deserves attention without being treated as a recommendation. It combined the highest fibrosis-response percentage in this study with fewer discontinuations than the 10 mg arm. That is a development signal for researchers, not dosing guidance for patients or clinicians.

How semaglutide changes the context

Semaglutide is not merely a familiar comparator. The current US Wegovy label includes treatment of noncirrhotic MASH with F2 to F3 fibrosis in adults under accelerated approval. The label says continued approval may depend on confirmation and description of clinical benefit in a confirmatory trial[3]. Readers can find the product's broader status and limits in our United States semaglutide regulation guide.

That regulatory context raises the bar for interpreting a new MASH candidate. Showing a histology effect against placebo is an important phase 2 result. It is not yet evidence of better long-term clinical outcomes, superiority to an approved option or regulatory approval. Later trials will need to clarify all three questions.

What we don't yet know

The study lasted 52 weeks and used biopsy-based surrogate endpoints. We do not yet know whether efinopegdutide reduces progression to cirrhosis, liver-related complications, transplantation or death. We also lack long-term safety data and a definitive comparison with semaglutide. The trial population excluded people with cirrhosis and several important medical histories, including pancreatitis and recent major cardiovascular events, which limits how far the findings can be generalised[2].

The sponsor was Merck Sharp & Dohme, a subsidiary of Merck & Co. Industry funding does not invalidate a randomised trial, but it is relevant context. Independent scrutiny, full publication of safety results and larger confirmatory studies will matter before the balance of benefit and harm is clear.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

What is efinopegdutide?

Efinopegdutide is an investigational once-weekly medicine that acts at GLP-1 and glucagon receptors. It is being studied for MASH and is not an approved treatment.

Did efinopegdutide resolve MASH in the phase 2b trial?

At week 52, MASH resolution without worsening fibrosis occurred in 56%, 63% and 61% of evaluable participants in the 4 mg, 7 mg and 10 mg groups, compared with 13% on placebo. These are trial results, not a guarantee of benefit for an individual.

Was efinopegdutide better than semaglutide?

The trial does not establish that. It included an open-label semaglutide arm, but the reported efinopegdutide efficacy comparisons were against placebo. A powered, prespecified head-to-head comparison would be needed to support a superiority claim.

Is efinopegdutide approved for MASH?

No. Efinopegdutide remains investigational. A positive phase 2b result does not amount to regulatory approval, and further trials are needed to establish long-term clinical benefit and safety.

Sources

  1. [1]Efficacy and safety of efinopegdutide in adults with MASH and stage 2-3 fibrosis: phase 2b randomised placebo-controlled study (Lancet; 2026 Nov 9; PMID 43003105)Tier 1 · primary↩
  2. [2]ClinicalTrials.gov record NCT05877547: phase 2b study of efinopegdutide in adults with precirrhotic steatohepatitisTier 1 · primary↩
  3. [3]DailyMed: current US prescribing information for Wegovy (semaglutide)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars